Deciphera Pharmaceuticals (DCPH) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
November 5, 2020 4:01 PM ESTU.S. QINLOCK® Net Revenue of $14.7 Million in the First Full Quarter of Launch
Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway
Enrollment for QINLOCK Phase 3 INTRIGUE Study Expected to be Completed in Fourth Quarter 2020
DCC-3014 Phase 1 Study Results in Additional TGCT Patients to be Featured in an Oral Presentation at the CTOS 2020 Virtual Annual Meeting
Company to Host Conference Call Today at 4:30 PM ET
WALTHAM, Mass.--(BUSINESS... More
